Biased CXCR4 Partial Agonist for Progenitor Mobilization
A β-arrestin-biased CXCR4 ligand that mobilizes reparative progenitors without the hematologic side effects of full antagonism.
recovery biased pocket: allo · ▲ 0 · platform draft · 2026-05-02 12:35
🎁 Free tier: 3 design runs / 24h per IP. Each run
produces 4 candidates with full Compounding Lab Spec Sheets — no
signup needed.
Have an API key?
Target structure — CXCR4-TMSB4-axis
AlphaFold v6 · drag to rotate · scroll to zoom · UniProt P61073
Desired effect
Transiently desensitizes CXCR4 via arrestin-biased signaling to release marrow-resident MSC and endothelial progenitors into circulation, enhancing homing to injured tissue. Avoids the neutrophilia and thrombocytosis seen with plerixafor-class full antagonists.
Mechanism rationale
The peptide engages a CXCR4 extracellular vestibule allosteric site that uncouples Gαi from β-arrestin recruitment, producing biased internalization without sustained signaling blockade. Coupling to the TMSB4 reparative axis exploits the natural synergy where progenitor egress and thymosin-β4-driven angiogenesis cooperate. Albumin-tethering gives a once-weekly PK envelope suitable for outpatient recovery cycles.
Novelty basis
No commercial peptide exploits arrestin-biased CXCR4 modulation specifically for tissue recovery rather than oncology stem-cell harvest.
Strategic value
Buyer profile is regenerative-medicine biotechs and large pharma rebuilding tissue-repair franchises (Novartis post-Sandoz, Lilly's emerging regenerative bets, Takeda cell therapy). TAM includes post-MI recovery, diabetic wound healing, and post-surgical orthopedic recovery — easily $6-8B if even one indication clears. GTM is to license early to a cell-therapy company as a mobilization adjuvant (immediate revenue path) while running parallel proof-of-concept in chronic wound healing where a biased safety profile becomes the differentiating clinical narrative.
Design parameters
| Primary target | CXCR4-TMSB4-axis — P61073 |
|---|---|
| Secondary targets | VEGFR2 |
| Binding mode | biased |
| Pocket mode | allo |
| Modality hint | 9-11 aa head-to-tail cyclic peptide with one N-methylated backbone amide and C-terminal palmitoyl tail for albumin binding, weekly subcutaneous |